Abstract

RUIZ, Hugo et al. Metastásis intraabdominal y pélvica en cáncer de próstata resistente a terapia de bloqueo anrogénico total. Rev. venez. oncol. [online]. 2009, vol.21, n.4, pp.237-239. ISSN 0798-0582.

The common sites for metastasis of prostate cancer are lymphatic’s regional nodule, bladder, bones, lung, liver, a small percentile of cases are present in other localizations how retro peritoneum, mediastinum. The surgery and radiation therapy are the standard treatment for disease localizes lesions. The use of hormonal therapy is the principal oncological treatment for hormone sensitive tumors. Recently chemotherapy treatment are and therapeutic alternative for this kind of tumors. Androgenic suppression produces a decrease of the levels for specifically prostate antigen, regression of the measure mass tumors and a clinical stable period. Masculine patient of 60 years old with less differentiated prostate adenocarcinoma Gleason 10, locally advanced, underwent suppression androgenic treatment, which refer abdominal pain and increase of the hipogastric volume. The biopsy of the abdominal tumor: Metastatic less differentiated adenocarcinoma of the prostate. Chemotherapy with docetaxel improves the support for the patients with metastatic prostate cancer metastásico androgenic independence.

Keywords : Cancer; prostate; hormonal resistant; ablation therapy; chemotherapy; docetaxel.